 |
12 Diseases |  |
6 Trials |
|
6 Trials |  |
384 News |  |
| «123456» |
- | VRC01 / Acuitas Therap
Trial primary completion date: Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection Among Men and Transgender Persons Who Have Sex With Men (clinicaltrials.gov) - Oct 17, 2018
P2b, N=2700, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Feb 2022 --> Oct 2020
- | VRC01 / Acuitas Therap
Enrollment closed: Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection in Women (clinicaltrials.gov) - Oct 16, 2018
P2b, N=1900, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Feb 2022 --> Oct 2020 Recruiting --> Active, not recruiting
- | VRC01 / Acuitas Therap
Enrollment closed: Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection Among Men and Transgender Persons Who Have Sex With Men (clinicaltrials.gov) - Oct 16, 2018
P2b, N=2700, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | VRC01 / Acuitas Therap
Trial completion: Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB080-00-AB (VRC01LS), With Broad HIV-1 Neutralizing Activity, Administered Intravenously or Subcutaneously to Healthy Adults (clinicaltrials.gov) - Jul 27, 2018
P1, N=49, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | VRC01 / Acuitas Therap
Trial primary completion date: Safety and Virologic Effect of a Human Monoclonal Antibody (VRC01) Administered Intravenously to Adults During Early Acute HIV Infection (clinicaltrials.gov) - Jun 28, 2018
P1, N=24, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Trial primary completion date: Apr 2018 --> Nov 2018
- | VRC01 / Acuitas Therap
Trial completion date, Trial primary completion date: Evaluating the Safety and Antiviral Activity of Monoclonal Antibody VRC01 in HIV-Infected Infants Receiving Combination Antiretroviral Therapy (clinicaltrials.gov) - Jun 26, 2018
P1/2, N=68, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Apr 2018 --> Nov 2018 Trial completion date: Jun 2021 --> Sep 2020 | Trial primary completion date: Sep 2020 --> Dec 2019
- | VRC01 / Acuitas Therap
Enrollment closed: Evaluating the Safety, Pharmacokinetics, and Anti-Viral Activity of VRC01 and VRC01LS in the Serum and Mucosa of Healthy, HIV-Uninfected Adults (clinicaltrials.gov) - Jun 19, 2018
P1, N=74, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial completion date: Jun 2021 --> Sep 2020 | Trial primary completion date: Sep 2020 --> Dec 2019 Recruiting --> Active, not recruiting
- | VRC01 / Acuitas Therap
Trial completion date, Trial primary completion date: Evaluating the Safety and Antiviral Activity of Monoclonal Antibody VRC01 in HIV-Infected Infants Receiving Combination Antiretroviral Therapy (clinicaltrials.gov) - Jun 6, 2018
P1/2, N=68, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Active, not recruiting Trial completion date: Jan 2020 --> Jun 2021 | Trial primary completion date: May 2019 --> Sep 2020
- | VRC01 / Acuitas Therap
Trial primary completion date: Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection in Women (clinicaltrials.gov) - Mar 30, 2018
P2b, N=1900, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial completion date: Jan 2020 --> Jun 2021 | Trial primary completion date: May 2019 --> Sep 2020 Trial primary completion date: Jul 2020 --> Dec 2021
- | VRC01 / Acuitas Therap
Trial primary completion date: Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection Among Men and Transgender Persons Who Have Sex With Men (clinicaltrials.gov) - Mar 30, 2018
P2b, N=2700, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Jul 2020 --> Dec 2021 Trial primary completion date: Aug 2020 --> Feb 2022
- | VRC01 / Acuitas Therap
Trial initiation date: Evaluating the Safety, Tolerability, and Effect of a Human Monoclonal Antibody (VRC01) on Markers of HIV Persistence in HIV-Infected Adults Receiving Antiretroviral Therapy (ART) (clinicaltrials.gov) - Feb 22, 2018
P1, N=40, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Aug 2020 --> Feb 2022 Initiation date: May 2015 --> Aug 2015
- | VRC01 / Acuitas Therap
Trial initiation date: Evaluating the Safety and Antiviral Activity of Monoclonal Antibody VRC01 in HIV-Infected Infants Receiving Combination Antiretroviral Therapy (clinicaltrials.gov) - Feb 19, 2018
P1/2, N=68, Not yet recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Initiation date: May 2015 --> Aug 2015 Initiation date: Jan 2018 --> May 2018
- | VRC01 / Acuitas Therap
Trial completion, Enrollment change, Trial primary completion date: VRC-HIVMAB060-00-AB (VRC01) in People With Chronic HIV Infection Undergoing Analytical Treatment Interruption (clinicaltrials.gov) - Oct 31, 2017
P1, N=10, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Initiation date: Jan 2018 --> May 2018 Active, not recruiting --> Completed | N=14 --> 10 | Trial primary completion date: Aug 2017 --> Apr 2017
- | VRC01 / Acuitas Therap
Enrollment change: Evaluating the Safety, Pharmacokinetics, and Anti-Viral Activity of VRC01 and VRC01LS in the Serum and Mucosa of Healthy, HIV-Uninfected Adults (clinicaltrials.gov) - Oct 26, 2017
P1, N=74, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed | N=14 --> 10 | Trial primary completion date: Aug 2017 --> Apr 2017 N=101 --> 74
- | VRC01 / Acuitas Therap
Trial completion: Safety and Therapeutic Efficacy of the VRC01 Antibody in Patients Who Initiated Antiretroviral Therapy During Early Acute HIV Infection (clinicaltrials.gov) - Oct 11, 2017
P2, N=24, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=101 --> 74 Active, not recruiting --> Completed
- | VRC01 / Acuitas Therap
Enrollment change: Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB080-00-AB (VRC01LS), With Broad HIV-1 Neutralizing Activity, Administered Intravenously or Subcutaneously to Healthy Adults (clinicaltrials.gov) - Sep 18, 2017
P1, N=45, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed N=30 --> 45
- | VRC01 / Acuitas Therap
Enrollment closed, Enrollment change: Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB080-00-AB (VRC01LS), With Broad HIV-1 Neutralizing Activity, Administered Intravenously or Subcutaneously to Healthy Adults (clinicaltrials.gov) - Sep 8, 2017
P1, N=30, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=30 --> 45 Recruiting --> Active, not recruiting | N=60 --> 30
- | VRC01 / Acuitas Therap
Trial primary completion date: Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB080-00-AB (VRC01LS), With Broad HIV-1 Neutralizing Activity, Administered Intravenously or Subcutaneously to Healthy Adults (clinicaltrials.gov) - Sep 7, 2017
P1, N=60, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Active, not recruiting | N=60 --> 30 Trial primary completion date: Aug 2017 --> Aug 2018
- | VRC01 / Acuitas Therap
New P1/2 trial: Evaluating the Safety and Antiviral Activity of Monoclonal Antibody VRC01 in HIV-Infected Infants Receiving Combination Antiretroviral Therapy (clinicaltrials.gov) - Jul 5, 2017
P1/2, N=68, Not yet recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- | VRC01 / Acuitas Therap
Enrollment open: Evaluating the Safety, Pharmacokinetics, and Anti-Viral Activity of VRC01 and VRC01LS in the Serum and Mucosa of Healthy, HIV-Uninfected Adults (clinicaltrials.gov) - Mar 10, 2017
P1, N=101, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Aug 2017 --> Aug 2018 Not yet recruiting --> Recruiting
- | VRC01 / Acuitas Therap
Enrollment closed: Safety and Therapeutic Efficacy of the VRC01 Antibody in Patients Who Initiated Antiretroviral Therapy During Early Acute HIV Infection (clinicaltrials.gov) - Mar 8, 2017
P2, N=24, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- VRC01 / Acuitas Therap
Trial primary completion date: Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB080-00-AB (VRC01LS), With Broad HIV-1 Neutralizing Activity, Administered Intravenously or Subcutaneously to Healthy Adults (clinicaltrials.gov) - Jan 10, 2017
P1, N=60, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2016 --> Aug 2017
- VRC01 / Acuitas Therap
Enrollment change: Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB080-00-AB (VRC01LS), With Broad HIV-1 Neutralizing Activity, Administered Intravenously or Subcutaneously to Healthy Adults (clinicaltrials.gov) - Dec 6, 2016
P1, N=60, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Dec 2016 --> Aug 2017 N=40 --> 60
- VRC01 / Acuitas Therap
Trial primary completion date: Evaluating the Safety, Tolerability, and Effect of a Human Monoclonal Antibody (VRC01) on Markers of HIV Persistence in HIV-Infected Adults Receiving Antiretroviral Therapy (ART) (clinicaltrials.gov) - Nov 10, 2016
P1, N=40, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=40 --> 60 Trial primary completion date: Sep 2016 --> Apr 2016
- VRC01 / Acuitas Therap
Trial primary completion date: Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection Among Men and Transgender Persons Who Have Sex With Men (clinicaltrials.gov) - Oct 18, 2016
P2b, N=2700, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Sep 2016 --> Apr 2016 Trial primary completion date: Jul 2019 --> Jul 2020
- VRC01 / Acuitas Therap
Trial completion: Evaluating the Safety, Tolerability, and Effect of a Human Monoclonal Antibody (VRC01) on Markers of HIV Persistence in HIV-Infected Adults Receiving Antiretroviral Therapy (ART) (clinicaltrials.gov) - Oct 12, 2016
P1, N=40, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Jul 2019 --> Jul 2020 Active, not recruiting --> Completed
- VRC01 / Acuitas Therap
Enrollment open, Trial primary completion date: Safety and Therapeutic Efficacy of the VRC01 Antibody in Patients Who Initiated Antiretroviral Therapy During Early Acute HIV Infection (clinicaltrials.gov) - Oct 3, 2016
P2, N=24, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Trial primary completion date: Sep 2016 --> Jul 2017
- | VRC01 / Acuitas Therap
Enrollment open: Safety and Virologic Effect of a Human Monoclonal Antibody (VRC01) Administered Intravenously to Adults During Early Acute HIV Infection (clinicaltrials.gov) - Oct 3, 2016
P1, N=24, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting --> Recruiting | Trial primary completion date: Sep 2016 --> Jul 2017 Not yet recruiting --> Recruiting
- VRC01 / Acuitas Therap
Trial primary completion date: VRC-HIVMAB060-00-AB (VRC01) in People With Chronic HIV Infection Undergoing Analytical Treatment Interruption (clinicaltrials.gov) - Sep 6, 2016
P1, N=14, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting --> Recruiting Trial primary completion date: Aug 2016 --> Aug 2017
- VRC01 / Acuitas Therap
Trial primary completion date: Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection Among Men and Transgender Persons Who Have Sex With Men (clinicaltrials.gov) - Aug 30, 2016
P2b, N=2700, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Aug 2016 --> Aug 2017 Trial primary completion date: Sep 2020 --> Jul 2019
- VRC01 / Acuitas Therap
Phase classification: Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection Among Men and Transgender Persons Who Have Sex With Men (clinicaltrials.gov) - Jun 15, 2016
P2b, N=2700, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Sep 2020 --> Jul 2019 Phase classification: P2 --> P2b
- VRC01 / Acuitas Therap
New P1 trial: Evaluating the Safety, Pharmacokinetics, and Anti-Viral Activity of VRC01 and VRC01LS in the Serum and Mucosa of Healthy, HIV-Uninfected Adults (clinicaltrials.gov) - Jun 13, 2016
P1, N=101, Not yet recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- VRC01 / Acuitas Therap
Phase classification: Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection in Women (clinicaltrials.gov) - Jun 10, 2016
P2b, N=1500, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Phase classification: P2 --> P2b Phase classification: P2 --> P2b
- VRC01 / Acuitas Therap
Enrollment open: Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection in Women (clinicaltrials.gov) - May 26, 2016
P2, N=1500, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Phase classification: P2 --> P2b Not yet recruiting --> Recruiting
- VRC01 / Acuitas Therap
Enrollment closed, Enrollment change, Trial primary completion date: VRC-HIVMAB060-00-AB (VRC01) in People With Chronic HIV Infection Undergoing Analytical Treatment Interruption (clinicaltrials.gov) - May 18, 2016
P1, N=14, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | N=45 --> 14 | Trial primary completion date: Jun 2017 --> Aug 2016
- VRC01 / Acuitas Therap
Enrollment open: Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection Among Men and Transgender Persons Who Have Sex With Men (clinicaltrials.gov) - Apr 27, 2016
P2, N=2700, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Active, not recruiting | N=45 --> 14 | Trial primary completion date: Jun 2017 --> Aug 2016 Not yet recruiting --> Recruiting
- VRC01 / Acuitas Therap
Clinical: Safety and Virologic Effect of a Human Monoclonal Antibody (VRC01) Administered Intravenously to Adults During Early Acute HIV Infection (clinicaltrials.gov) - Apr 21, 2016
P1, N=24, Not yet recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2016 --> Apr 2018
- VRC01 / Acuitas Therap
Trial completion: Evaluating the Safety, Pharmacokinetics, and Antiviral Activity of a Human Monoclonal Antibody (VRC01) in HIV-Infected Adults Undergoing a Brief Treatment Interruption (clinicaltrials.gov) - Apr 21, 2016
P1, N=14, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Dec 2016 --> Apr 2018 Active, not recruiting --> Completed
- VRC01 / Acuitas Therap
Trial completion, Trial primary completion date: Evaluating the Safety and Drug Levels of an Antibody Against HIV in Healthy, HIV-Uninfected Adults (clinicaltrials.gov) - Mar 31, 2016
P1, N=88, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Jun 2016 --> Mar 2016
- VRC01 / Acuitas Therap
Trial primary completion date: Evaluating the Safety, Pharmacokinetics, and Antiviral Activity of a Human Monoclonal Antibody (VRC01) in HIV-Infected Adults Undergoing a Brief Treatment Interruption (clinicaltrials.gov) - Mar 30, 2016
P1, N=15, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed | Trial primary completion date: Jun 2016 --> Mar 2016 Trial primary completion date: Jul 2016 --> Mar 2016
- | VRC01 / Acuitas Therap
New P2 trial: Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection Among Men and Transgender Persons Who Have Sex With Men (clinicaltrials.gov) - Mar 23, 2016
P2, N=2700, Not yet recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- VRC01 / Acuitas Therap
Enrollment closed: Evaluating the Safety, Tolerability, and Effect of a Human Monoclonal Antibody (VRC01) on Markers of HIV Persistence in HIV-Infected Adults Receiving Antiretroviral Therapy (ART) (clinicaltrials.gov) - Mar 21, 2016
P1, N=40, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Jul 2016 --> Mar 2016 Recruiting --> Active, not recruiting
- VRC01 / Acuitas Therap
Enrollment change, Trial primary completion date: Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection in Women (clinicaltrials.gov) - Mar 18, 2016
P2, N=1500, Not yet recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Active, not recruiting N=3900 --> 1500 | Trial primary completion date: Dec 2022 --> Aug 2020
- VRC01 / Acuitas Therap
Trial primary completion date: Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection in Women (clinicaltrials.gov) - Feb 24, 2016
P2, N=3900, Not yet recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=3900 --> 1500 | Trial primary completion date: Dec 2022 --> Aug 2020 Trial primary completion date: Dec 2021 --> Dec 2022
- VRC01 / Acuitas Therap
New P2 trial: Safety and Therapeutic Efficacy of the VRC01 Antibody in Patients Who Initiated Antiretroviral Therapy During Early Acute HIV Infection (clinicaltrials.gov) - Jan 27, 2016
P2, N=24, Not yet recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- VRC01 / Acuitas Therap
Enrollment closed: Evaluating the Safety, Pharmacokinetics, and Antiviral Activity of a Human Monoclonal Antibody (VRC01) in HIV-Infected Adults Undergoing a Brief Treatment Interruption (clinicaltrials.gov) - Jan 25, 2016
P1, N=15, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Dec 2021 --> Dec 2022 Recruiting --> Active, not recruiting
- VRC01 / Acuitas Therap
New P1 trial: Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB080-00-AB (VRC01LS), With Broad HIV-1 Neutralizing Activity, Administered Intravenously or Subcutaneously to Healthy Adults (clinicaltrials.gov) - Nov 9, 2015
P1, N=40, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- | VRC01 / Acuitas Therap
New P1 trial: Safety and Virologic Effect of a Human Monoclonal Antibody (VRC01) Administered Intravenously to Adults During Early Acute HIV Infection (clinicaltrials.gov) - Oct 29, 2015
P1, N=24, Not yet recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- | VRC01 / Acuitas Therap
New P2 trial: Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection in Women (clinicaltrials.gov) - Oct 5, 2015
P2, N=3900, Not yet recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- VRC01 / Acuitas Therap
Enrollment open: Evaluating the Safety, Pharmacokinetics, and Antiviral Activity of a Human Monoclonal Antibody (VRC01) in HIV-Infected Adults Undergoing a Brief Treatment Interruption (clinicaltrials.gov) - Sep 17, 2015
P1, N=15, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting